RS55431B1 - Kristalni tripeptidni epoksiketonski inhibitori proteaze - Google Patents
Kristalni tripeptidni epoksiketonski inhibitori proteazeInfo
- Publication number
- RS55431B1 RS55431B1 RS20161122A RSP20161122A RS55431B1 RS 55431 B1 RS55431 B1 RS 55431B1 RS 20161122 A RS20161122 A RS 20161122A RS P20161122 A RSP20161122 A RS P20161122A RS 55431 B1 RS55431 B1 RS 55431B1
- Authority
- RS
- Serbia
- Prior art keywords
- protease inhibitors
- epoxy ketone
- ketone protease
- tripeptide epoxy
- crystalline tripeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16219609P | 2009-03-20 | 2009-03-20 | |
| US18056109P | 2009-05-22 | 2009-05-22 | |
| EP14178725.9A EP2813241B1 (en) | 2009-03-20 | 2010-03-22 | Crystalline tripeptide epoxy ketone protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55431B1 true RS55431B1 (sr) | 2017-04-28 |
Family
ID=42738216
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150015A RS53746B1 (sr) | 2009-03-20 | 2010-03-22 | Kristalni tripeptidni epoksiketonski inhibitori proteaze |
| RS20161122A RS55431B1 (sr) | 2009-03-20 | 2010-03-22 | Kristalni tripeptidni epoksiketonski inhibitori proteaze |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150015A RS53746B1 (sr) | 2009-03-20 | 2010-03-22 | Kristalni tripeptidni epoksiketonski inhibitori proteaze |
Country Status (45)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1948678T3 (pl) | 2005-11-09 | 2013-09-30 | Onyx Therapeutics Inc | Związki do hamowania enzymów |
| DK2041158T3 (da) | 2006-06-19 | 2013-06-24 | Onyx Therapeutics Inc | Peptid-epoxidketoner til proteasom inhibering |
| KR20150131405A (ko) | 2007-10-04 | 2015-11-24 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| EP2349313A4 (en) | 2008-10-21 | 2012-08-29 | Onyx Therapeutics Inc | COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| EP3153020B1 (en) | 2009-10-07 | 2018-11-28 | Dow AgroSciences LLC | Synergistic fungicidial mixtures for fungal control in cereals |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| MX2012010017A (es) | 2010-03-01 | 2012-10-01 | Onyx Therapeutics Inc | Compuestos de para la inhibicion de inmunoproteasomas. |
| CN102946729B (zh) | 2010-04-07 | 2014-11-05 | 欧尼斯治疗公司 | 结晶肽环氧酮免疫蛋白酶体抑制剂 |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| EP2883960B1 (en) * | 2012-08-10 | 2020-05-13 | Ajinomoto Co., Inc. | METHOD FOR PRODUCING gamma-GLUTAMYL-VALYL-GLYCINE CRYSTAL |
| TW201422255A (zh) * | 2012-10-24 | 2014-06-16 | Onyx Therapeutics Inc | 用於蛋白酶體抑制劑之調整釋放製劑 |
| ES2666144T3 (es) | 2012-12-28 | 2018-05-03 | Dow Agrosciences Llc | Mezclas fungicidas sinérgicas para control fúngico en cereales |
| US9549556B2 (en) | 2013-12-26 | 2017-01-24 | Dow Agrosciences Llc | Macrocyclic picolinamides as fungicides |
| CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
| CN104974221B (zh) * | 2014-04-03 | 2020-10-23 | 中国医学科学院药物研究所 | 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途 |
| EP3166936A4 (en) | 2014-07-08 | 2017-11-22 | Dow AgroSciences LLC | Macrocyclic picolinamides as fungicides |
| US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
| CA2972405A1 (en) | 2014-12-30 | 2016-07-07 | Dow Agrosciences Llc | Use of picolinamide compounds as fungicides |
| RU2702697C2 (ru) | 2014-12-30 | 2019-10-09 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Использование пиколинамидных соединений с фунгицидной активностью |
| AU2015374458B2 (en) | 2014-12-30 | 2018-02-15 | Dow Agrosciences Llc | Use of picolinamide compounds with fungicidal activity |
| RU2703402C2 (ru) | 2014-12-30 | 2019-10-16 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Пиколинамиды с фунгицидной активностью |
| WO2016109305A1 (en) | 2014-12-30 | 2016-07-07 | Dow Agrosciences Llc | Use of picolinamides as fungicides |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| KR102655020B1 (ko) | 2016-06-29 | 2024-04-04 | 케자르 라이프 사이언스 | 펩티드 에폭시케톤 면역프로테아좀 억제제의 결정질 염 |
| EA201990157A1 (ru) | 2016-06-29 | 2019-05-31 | Кезар Лайф Сайнсиз | Способ получения пептидного эпоксикетонового ингибитора иммунопротеасомы и его предшественников |
| WO2018044996A1 (en) | 2016-08-30 | 2018-03-08 | Dow Agrosciences Llc | Picolinamides as fungicides |
| WO2018045003A1 (en) | 2016-08-30 | 2018-03-08 | Dow Agrosciences Llc | Picolinamide n-oxide compounds with fungicidal activity |
| US10231452B2 (en) | 2016-08-30 | 2019-03-19 | Dow Agrosciences Llc | Thiopicolinamide compounds with fungicidal activity |
| US10334852B2 (en) | 2016-08-30 | 2019-07-02 | Dow Agrosciences Llc | Pyrido-1,3-oxazine-2,4-dione compounds with fungicidal activity |
| WO2018057453A1 (en) | 2016-09-21 | 2018-03-29 | Amgen Inc. | Immediate release formulations for oprozomib |
| JP2018123119A (ja) | 2016-12-14 | 2018-08-09 | アムジエン・インコーポレーテツド | オプロゾミブのための胃内保持型の徐放性剤形、及びその調製プロセス |
| BR102018000183B1 (pt) | 2017-01-05 | 2023-04-25 | Dow Agrosciences Llc | Picolinamidas, composição para controle de um patógeno fúngico, e método para controle e prevenção de um ataque por fungos em uma planta |
| EP3618626A4 (en) | 2017-05-02 | 2020-12-02 | Dow Agrosciences LLC | USE OF AN ACYCLIC PICOLINAMIDE COMPOUND AS A FUNGICIDE FOR FUNGAL GRASS INFESTATION |
| TWI774761B (zh) | 2017-05-02 | 2022-08-21 | 美商科迪華農業科技有限責任公司 | 用於穀物中的真菌防治之協同性混合物 |
| TW201842851A (zh) | 2017-05-02 | 2018-12-16 | 美商陶氏農業科學公司 | 用於穀類中的真菌防治之協同性混合物 |
| CN111108125A (zh) | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| BR102019004480B1 (pt) | 2018-03-08 | 2023-03-28 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
| CA3115684A1 (en) | 2018-10-15 | 2020-04-23 | Dow Agrosciences Llc | Methods for sythesis of oxypicolinamides |
| CN118255835A (zh) * | 2022-12-27 | 2024-06-28 | 上海美悦生物科技发展有限公司 | 三肽环氧酮化合物、药物组合物及其制备方法和用途 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| US5441944A (en) | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
| US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
| US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| IL97428A0 (en) | 1990-03-05 | 1992-06-21 | Cephalon Inc | Chymotrypsin-like proteases and their inhibitors |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| ATE195553T1 (de) * | 1992-06-09 | 2000-09-15 | Chiron Corp | Kristallisierung von m-csf |
| GB9300048D0 (en) | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
| TW380137B (en) | 1994-03-04 | 2000-01-21 | Merck & Co Inc | Process for making an epoxide |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| DE19505263A1 (de) | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| EP2409985A3 (en) | 1996-10-18 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus |
| SI0932617T1 (en) | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| DE69819721T2 (de) | 1997-06-13 | 2004-09-23 | Cydex Inc., Overland Park | Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden |
| US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
| US6100282A (en) * | 1998-01-02 | 2000-08-08 | Hoffman-La Roche Inc. | Thiazole derivatives |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| US6099851A (en) | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
| US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
| US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| BR9914648A (pt) | 1998-10-20 | 2001-11-27 | Millennium Pharm Inc | Processo para monitorar ação medicamentosa deinibidor de proteasoma |
| US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| WO2001028579A2 (en) | 1999-10-20 | 2001-04-26 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
| DE50110956D1 (de) | 2000-10-12 | 2006-10-19 | Viromics Gmbh | Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen |
| GB0114185D0 (en) * | 2001-06-12 | 2001-08-01 | Protherics Molecular Design Lt | Compounds |
| CA2435146C (en) | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| DK1392355T3 (da) | 2001-05-21 | 2007-04-30 | Alcon Inc | Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser |
| AU2003219652A1 (en) | 2002-01-08 | 2003-07-30 | Eisai Co. Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
| US20040116329A1 (en) | 2002-01-29 | 2004-06-17 | Epstein Stephen E. | Inhibition of proteasomes to prevent restenosis |
| CA2481306A1 (en) | 2002-04-09 | 2003-10-23 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20030224469A1 (en) | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
| US7902185B2 (en) | 2002-06-03 | 2011-03-08 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative diseases using proteasome modulators |
| AU2003256847A1 (en) | 2002-07-26 | 2004-02-16 | Advanced Research And Technology Institute At Indiana University | Method of treating cancer |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| PE20130200A1 (es) | 2003-04-08 | 2013-03-09 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
| WO2005004798A2 (en) | 2003-06-10 | 2005-01-20 | The J. David Gladstone Institutes | Methods for treating lentivirus infections |
| US7012063B2 (en) | 2003-06-13 | 2006-03-14 | Children's Medical Center Corporation | Reducing axon degeneration with proteasome inhibitors |
| NZ548225A (en) | 2003-12-31 | 2012-12-21 | Cydex Pharmaceuticals Inc | Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid |
| GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
| US20050228031A1 (en) * | 2004-04-13 | 2005-10-13 | Bilodeau Mark T | Tyrosine kinase inhibitors |
| US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CN102174076A (zh) | 2004-04-15 | 2011-09-07 | 普罗特奥里克斯公司 | 用于抑制蛋白酶体酶的化合物 |
| WO2005111009A2 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
| DK2030981T3 (da) | 2004-05-10 | 2014-10-13 | Onyx Therapeutics Inc | Forbindelser til proteasom-enzymhæmning |
| CN101044157B (zh) * | 2004-08-06 | 2011-07-13 | 普罗特奥里克斯公司 | 用于抑制蛋白酶体的化合物 |
| AU2005295183A1 (en) | 2004-10-20 | 2006-04-27 | CAOnyx Therapeutics, Inc. | Labeled compounds for proteasome inhibition |
| DK1819353T3 (da) | 2004-12-07 | 2011-05-16 | Proteolix Inc | Sammensætning til proteasomhæmning |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7589066B2 (en) | 2005-03-11 | 2009-09-15 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| PL1948678T3 (pl) | 2005-11-09 | 2013-09-30 | Onyx Therapeutics Inc | Związki do hamowania enzymów |
| AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
| US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| WO2007122686A1 (ja) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
| DK2041158T3 (da) | 2006-06-19 | 2013-06-24 | Onyx Therapeutics Inc | Peptid-epoxidketoner til proteasom inhibering |
| WO2008033807A2 (en) | 2006-09-13 | 2008-03-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer |
| US8601054B2 (en) * | 2006-12-07 | 2013-12-03 | International Business Machines Corporation | Project-related communications |
| CA2676387A1 (en) | 2007-01-23 | 2008-07-31 | Gloucester Pharmaceuticals, Inc. | Combination therapy |
| WO2008140782A2 (en) * | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| KR20150010802A (ko) | 2007-08-06 | 2015-01-28 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아좀 억제제 |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| KR20150131405A (ko) * | 2007-10-04 | 2015-11-24 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| JP5600595B2 (ja) | 2007-10-16 | 2014-10-01 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | プロテアソーム阻害剤 |
| US20090131367A1 (en) | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| KR101690571B1 (ko) | 2008-06-17 | 2016-12-28 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 보로네이트 에스테르 화합물 및 이의 제약학적 조성물 |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| EP2349313A4 (en) | 2008-10-21 | 2012-08-29 | Onyx Therapeutics Inc | COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| CN101928329B (zh) | 2009-06-19 | 2013-07-17 | 北京大学 | 三肽硼酸(酯)类化合物、其制备方法和应用 |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| MX2012010017A (es) | 2010-03-01 | 2012-10-01 | Onyx Therapeutics Inc | Compuestos de para la inhibicion de inmunoproteasomas. |
| CN102892291A (zh) | 2010-03-31 | 2013-01-23 | 米伦纽姆医药公司 | 1-氨基-2-环丙基乙硼酸衍生物 |
| CN102946729B (zh) | 2010-04-07 | 2014-11-05 | 欧尼斯治疗公司 | 结晶肽环氧酮免疫蛋白酶体抑制剂 |
-
2010
- 2010-03-19 AR ARP100100894A patent/AR075899A1/es unknown
- 2010-03-19 TW TW099108136A patent/TWI504598B/zh not_active IP Right Cessation
- 2010-03-20 SA SA110310221A patent/SA110310221B1/ar unknown
- 2010-03-20 SA SA114350283A patent/SA114350283B1/ar unknown
- 2010-03-22 US US12/728,547 patent/US20100240903A1/en not_active Abandoned
- 2010-03-22 BR BRPI1009369A patent/BRPI1009369A2/pt not_active Application Discontinuation
- 2010-03-22 MX MX2013012107A patent/MX343562B/es unknown
- 2010-03-22 EP EP14178725.9A patent/EP2813241B1/en active Active
- 2010-03-22 SI SI201030833T patent/SI2408758T1/sl unknown
- 2010-03-22 AP AP2013007137A patent/AP3513A/xx active
- 2010-03-22 SG SG2014011373A patent/SG2014011373A/en unknown
- 2010-03-22 US US13/257,887 patent/US8604215B2/en not_active Expired - Fee Related
- 2010-03-22 ME MEP-2011-164A patent/ME01277B/me unknown
- 2010-03-22 PL PL10754225T patent/PL2408758T3/pl unknown
- 2010-03-22 CA CA2755971A patent/CA2755971C/en not_active Expired - Fee Related
- 2010-03-22 SI SI201031354A patent/SI2813241T1/sl unknown
- 2010-03-22 RS RS20150015A patent/RS53746B1/sr unknown
- 2010-03-22 MY MYPI2011004414A patent/MY156522A/en unknown
- 2010-03-22 EA EA201300860A patent/EA024672B1/ru not_active IP Right Cessation
- 2010-03-22 ES ES10754225.0T patent/ES2527619T3/es active Active
- 2010-03-22 PE PE2011001673A patent/PE20120645A1/es active IP Right Grant
- 2010-03-22 AU AU2010226410A patent/AU2010226410B2/en not_active Ceased
- 2010-03-22 KR KR1020117022814A patent/KR101729344B1/ko active IP Right Grant
- 2010-03-22 MA MA34254A patent/MA33197B1/fr unknown
- 2010-03-22 ES ES14178725.9T patent/ES2614557T3/es active Active
- 2010-03-22 NZ NZ61843210A patent/NZ618432A/en not_active IP Right Cessation
- 2010-03-22 LT LTEP14178725.9T patent/LT2813241T/lt unknown
- 2010-03-22 RS RS20161122A patent/RS55431B1/sr unknown
- 2010-03-22 PT PT107542250T patent/PT2408758E/pt unknown
- 2010-03-22 EP EP10754225.0A patent/EP2408758B1/en active Active
- 2010-03-22 MX MX2011009777A patent/MX2011009777A/es active IP Right Grant
- 2010-03-22 NZ NZ595847A patent/NZ595847A/en not_active IP Right Cessation
- 2010-03-22 SG SG2011067204A patent/SG174446A1/en unknown
- 2010-03-22 DK DK14178725.9T patent/DK2813241T3/en active
- 2010-03-22 WO PCT/US2010/028126 patent/WO2010108172A1/en active Application Filing
- 2010-03-22 EA EA201171151A patent/EA020973B1/ru not_active IP Right Cessation
- 2010-03-22 CN CN201080021879.8A patent/CN102428075B/zh not_active Expired - Fee Related
- 2010-03-22 JP JP2012501028A patent/JP5723357B2/ja active Active
- 2010-03-22 PL PL14178725T patent/PL2813241T3/pl unknown
- 2010-03-22 PT PT141787259T patent/PT2813241T/pt unknown
- 2010-03-22 DK DK10754225.0T patent/DK2408758T3/da active
- 2010-03-22 HU HUE14178725A patent/HUE032430T2/en unknown
- 2010-03-22 GE GEAP201012421A patent/GEP20156392B/en unknown
-
2011
- 2011-09-15 IL IL215174A patent/IL215174A/en not_active IP Right Cessation
- 2011-09-16 CO CO11120506A patent/CO6430433A2/es not_active Application Discontinuation
- 2011-09-16 DO DO2011000286A patent/DOP2011000286A/es unknown
- 2011-09-19 TN TN2011000470A patent/TN2011000470A1/fr unknown
- 2011-09-19 CR CR20110491A patent/CR20110491A/es unknown
- 2011-09-19 ZA ZA2011/06826A patent/ZA201106826B/en unknown
- 2011-09-20 NI NI201100170A patent/NI201100170A/es unknown
- 2011-09-20 CU CU20110176A patent/CU20110176A7/es unknown
- 2011-09-20 EC EC2011011341A patent/ECSP11011341A/es unknown
- 2011-09-20 HN HN2011002459A patent/HN2011002459A/es unknown
- 2011-09-20 CL CL2011002326A patent/CL2011002326A1/es unknown
- 2011-09-20 US US13/237,655 patent/US8822512B2/en not_active Expired - Fee Related
-
2012
- 2012-03-15 HK HK12102641.5A patent/HK1162476A1/xx not_active IP Right Cessation
-
2013
- 2013-09-24 US US14/035,644 patent/US9051353B2/en not_active Expired - Fee Related
-
2015
- 2015-01-08 HR HRP20150014AT patent/HRP20150014T1/hr unknown
- 2015-01-12 SM SM201500009T patent/SMT201500009B/xx unknown
- 2015-03-05 US US14/639,603 patent/US9403868B2/en not_active Expired - Fee Related
- 2015-06-16 HK HK15105658.5A patent/HK1204952A1/xx not_active IP Right Cessation
-
2016
- 2016-03-11 ZA ZA2016/01686A patent/ZA201601686B/en unknown
- 2016-12-06 HR HRP20161654TT patent/HRP20161654T1/hr unknown
- 2016-12-16 CY CY20161101307T patent/CY1118359T1/el unknown
-
2017
- 2017-01-30 SM SM201700068T patent/SMT201700068B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201601686B (en) | Crystalline tripeptide epoxy ketone protease inhibitors | |
| ZA201202631B (en) | Hcv protease inhibitors | |
| EP2274281A4 (en) | HCV PROTEASE INHIBITORS | |
| IL222330A0 (en) | Crystalline peptide epoxyketone immunoproteasome inhibitor | |
| ZA201107636B (en) | Protease inhibitors | |
| EP2509956A4 (en) | INHIBITORS OF CYSTEINE PROTEASES | |
| EP2313426A4 (en) | NOVEL PROTEASE INHIBITORS | |
| ZA201102179B (en) | Protease inhibitors | |
| ZA201200811B (en) | Cathepsin c inhibitors | |
| GB0817425D0 (en) | Protease inhibitors | |
| AP2912A (en) | Crystalline tripeptide epoxy protease inhibitors | |
| HK1155175A1 (en) | Hcv protease inhibitors | |
| SG2014011258A (en) | Hcv protease inhibitors | |
| AU2009902963A0 (en) | Novel protease inhibitors | |
| TWM379488U (en) | Improved screwdriver stem | |
| GB0915927D0 (en) | Novel inhibitors | |
| GB0902661D0 (en) | Inhibitors | |
| GB0903650D0 (en) | Glyoalase inhibitors |